Source: Annual Congress 2006 - COPD – therapy/exacerbations
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Damianaki, D. Makris, M. Kokosi, E. Ntaoukakis, N. M. Siafakas, N. Tzanakis (Heraklion, Greece). Frequent exacerbations in COPD are associated with accelerated rate of FEV₁ decline. Eur Respir J 2006; 28: Suppl. 50, 302

Member's Comments

No comment yet.

Related content which might interest you: Frequent exacerbations in ex smokers with COPD are associated with accelerated rate of FEV1 decline Source: Eur Respir J 2005; 26: Suppl. 49, 510s Year: 2005 Regular follow-up in severe asthma may reduce the rate of exacerbations and the FEV1 decline Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Decline in FEV1 is faster with frequent exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Cardiac disease from accelerated FEV1 decline and acute exacerbations: time to rethink comorbidities in COPD Source: Eur Respir J, 57 (3) 2004008; 10.1183/13993003.04008-2020 Year: 2021 Tiotropium: COPD exacerbations and decline in FEV1 Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 ADAM33 SNPs are associated with excess FEV1 decline in severe early onset COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 Predictors for the rapid decline of FEV1 in chronic obstructive lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 255s Year: 2002 The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Determinants of exacerbation rate in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 661s Year: 2004 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 Exacerbation frequency and FEV1 decline of COPD: is it geographic? Source: Eur Respir J 2014; 43: 1220-1222 Year: 2014 Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Changes in FEV1 and SpO2 in patients with severe and very severe COPD Source: Virtual Congress 2021 – Lung function testing in the management of obstructive diseases Year: 2021 Increasing risk of exacerbation and mortality associated with increasing frequency and severity of exacerbations in COPD patients: EXACOS-UK Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Individual decline of FEV1 show diversity in COPD Source: Annual Congress 2012 - Environmental exposure and other risk factors for airway diseases Year: 2012 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Acute exacerbation is not related to the decline of airway calibre in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 184s Year: 2001 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018